A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500115-39-00

Acronym

ADCT-901-101

Enrollment

Registered

2022-07-18

Start date

2022-12-23

Completion date

2024-02-22

Last updated

2023-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026